DALFAMPRIDINE ER (dalfampridine)
AMINOPYRIDINES FOR NEUROLOGICAL DISORDERS · WALKING IMPAIRMENT DUE TO MULTIPLE SCLEROSIS
TEVA USA
Drug class
Aminopyridines for Neurological Disorders
While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class, it designates monoamino and diamino pyridine derivatives that act as voltage-gated potassium channel blockers. Read more about Aminopyridines for Neurological Disorders
10 drugs in this class 9 manufacturers
Drugs in Aminopyridines for Neurological Disorders
Filter & compare in the drug finder →
Opens the drug finder with Aminopyridines for Neurological Disorders preselected. Add indication or manufacturer filters there.
While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class, it designates monoamino and diamino pyridine derivatives that act as voltage-gated potassium channel blockers.
By blocking exposed axonal potassium channels and prolonging presynaptic action potentials, these agents restore action potential conduction along demyelinated nerve fibers and promote calcium influx to enhance acetylcholine release.
Therapeutically, approved agents within this family—principally dalfampridine and amifampridine—are used for symptomatic management to improve walking ability in multiple sclerosis and to treat muscle weakness in Lambert-Eaton myasthenic syndrome.
-
nih.gov
While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class, it designates monoamino and diamino pyridine derivatives that act as voltage-gated potassium channel blockers
-
ovid.com
While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class Therapeutically, approved agents within this family—principally dalfampridine and amifampridine—are used for symptomatic management to improve walking ability in multiple sclerosis and to treat muscle weakness in Lambert-Eaton myasthenic syndrome
-
fda.gov
While "aminopyridines for neurological disorders" functions as a clinical and descriptive grouping in medical literature rather than a formal, standardized regulatory drug class, it designates monoamino and diamino pyridine derivatives that act as voltage-gated potassium channel blockers By blocking exposed axonal potassium channels and prolonging presynaptic action potentials, these agents restore action potential conduction along demyelinated nerve fibers and promote calcium influx to enhance ...
-
nih.gov
By blocking exposed axonal potassium channels and prolonging presynaptic action potentials, these agents restore action potential conduction along demyelinated nerve fibers and promote calcium influx to enhance acetylcholine release
-
clevelandclinic.org
Therapeutically, approved agents within this family—principally dalfampridine and amifampridine—are used for symptomatic management to improve walking ability in multiple sclerosis and to treat muscle weakness in Lambert-Eaton myasthenic syndrome
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.